Aktuella utlysningar, vecka 34, 2021
Grants Office tipsar om aktuella utlysningar.
Svenska och nordiska utlysningar
International postdoc within medicine and health - Swedish Research Council (VR)
Supports research in the field of medicine and health and enables researchers to expand their networks and competencies by working abroad. Grants are worth SEK 1.15 million per year for between 18 months and three years.
Closing date: 14 September 2021
International postdoc within natural and engineering sciences Swedish Research Council (VR)
Enables researchers in the field of natural and engineering sciences to expand their networks and their competencies by working abroad. Grants are worth SEK 1.15 million per year between 18 months and three years.
Closing date: 14 September 2021
International research award for mathematics, natural sciences and medicine - Olav Thon Foundation
Recognises excellent research in the field of mathematics, natural sciences and medicine. The award is worth NOK 5 million.
Closing date: 15 September 2021
Svenska Läkaresällskapet - Stiftelsen Söderström-Königska sjukhemmet
Stiftelsens delar i första hand ut anslag till forskningsprojekt som främjar psykiatrisk kunskapsutveckling (allmänpsykiatri, barn- och ungdomspsykiatri, äldrepsykiatri och rättspsykiatri). Styrelsen kommer vid bedömningen att lägga stor vikt vid nyttan för patienter med psykisk sjukdom samt vid forskning som uppmärksammar kvinnors speciella situation inom psykiatrin. Låg prioritet ges åt ansökningar med djurexperimentell inriktning.
Vid årets ansökningsomgång kan man söka projektanslag och/eller post doktorstöd från stiftelsen.
Closing date: 01 October 2021
Development projects in incubators 2021 to 2024 – Vinnova
This supports incubators to develop and test new working methods and tools as well as implement already developed working methods and tools that have proven to be effective in incubator operations. Grants are worth up to SEK 2 million and projects may last for up to two years. Maximum award: SEK 2,000,000
Closing date: 5 October 2021
Challenge programme: immunity at mucosal surfaces – Novo Nordisk Foundation
This supports projects that aim to translate knowledge of the mucosal immune system into novel treatments of disease and develop procedures that safely induce long-lasting protection against pathogens via unspecific immune responses at mucosal surfaces, or that maintain tolerance towards innocuous agents. Grants are worth up to DKK 10 million per year for up to six years. Maximum award: DKK 60,000,000
Closing date: 27 October 2021
Swedish Pharmaceutical Society
- Postdoc grants, support post doctoral research in pharmaceutical research either in Sweden or abroad.
- Travel grants for thesis work abroad from the Elisabeth and Alfred Ahlqvist Foundation
- Grants for research courses and congresses.
- Grants for shorter research stays abroad, support doctoral students to stay abroad for a short time.
- Pharmacies grants for good drug use: supports research projects in outpatient pharmacies.
Closing date: 31 October 2021
Utlysning av Kungliga och Hvitfeldtskas universitets-och högskolestipendium
Universitets- och högskolestipendium kan tilldelas studerande, som
- har slutbetyg från gymnasium i förutvarande Göteborg och Bohus län
- är född i Göteborgs stift eller var folkbokförd där när gymnasiestudierna påbörjades inom stiftet
- är mindre bemedlad
- inger goda förhoppningar om framgång i vetenskapliga studier
- Stipendiet utgör för närvarande 10.000 kronor.
Endast studerande som klarat av minst 60 poäng av grundutbildningen och har för avsikt att examineras vid statlig högskola eller universitet i Sverige samt Handelshögskolan i Stockholm och Chalmers Tekniska Högskola kan komma ifråga för stipendium. En studerande kan endast erhålla stipendiet en gång.
Ansökningshandlingar skall skickas till email@example.com
Closing date: October 9, 2021
Horizon Europe Pillar II collaborative calls
The calls in the Horizon Europe health cluster (Pillar II) aims to contribute to six expected impacts as set out by the strategic plan, which are the following six destinations of this work programme: Destination 1 - Staying healthy in a rapidly changing society. Destination 2 - Living and working in a health-promoting environment. Destination 3 - Tackling diseases and reducing disease burden. Destination 4 - Ensuring access to innovative, sustainable and high-quality health care. Destination 5 - Unlocking the full potential of new tools, technologies and digital solutions for a healthy society. Destination 6 - Maintaining an innovative, sustainable and globally competitive health-related industry.
Opportunities within Pillar II – Health 2022
Two-stage (Research and Innovation action)
Opening date: 06 October 2021
First stage deadline: 01 February 2022
Second stage deadline: 06 September 2022
- Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs
- Vaccines 2.0 - developing the next generation of vaccines
- Development of new effective therapies for rare diseases
- Computational models for new patient stratification strategies
- Boosting mental health in Europe in times of change
- Trustworthy artificial intelligence (AI) tools to predict the risk of chronic non-communicable diseases and/or their progression
- Prevention of obesity throughout the life course
Single-stage (Research and Innovation action)
Opening date: 12 January 2022
Closing date: 21 April 2022
- Pandemic preparedness
- Non-communicable diseases risk reduction in adolescence and youth (Global Alliance for Chronic Diseases - GACD)
- Methods for assessing health-related costs of environmental stressors
- Enhancing cybersecurity of connected medical devices
- Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation
- New pricing and payment models for cost-effective and affordable health innovations
- Setting up a European Smart Health Innovation Hub
- Setting up a European Electronic Health Record Exchange Format (EEHRxF) Ecosystem
- Personalised blueprint of chronic inflammation in health-to-disease transition
- Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers
- New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment
Fellowship project award - Bayer
Bayer, under its haemophilia awards programme, invites proposals for its fellowship project award. This supports the development of clinical and research expertise in the field of haemophilia for applicants who have completed medical training and have an interest in pursuing a career as a haemophilia clinician.
Applicants should be affiliated with either a medical university, hospital, treatment centre, blood centre or laboratory and should have earned their medical degree within the previous eight years.
Closing date: 30 November 2021
AO strategy fund - AO Foundation
The AO Foundation invites applications for its strategy fund. This supports the development of innovative products, services and technologies relevant to a clinical area in musculoskeletal disorders. Projects must focus on either clinical tools and technologies for any element of the entire patient journey in musculoskeletal disorders, from diagnosis to post-operative care; or educational tools, platforms or channels for lifelong training of surgeons. Applicants must become members of the AO clinical division. Support is provided in the form of seed funding. There is no pre-defined minimum or maximum amount of funding per project.
Closing date: 31 January 2022
Federal Funding agencies
Notice of Special Interest_Understand the Role of DEAD/H-box Helicases in Immune Homeostasis and Activation, NIH
NIAID aims to fund grant awards through the recently issued Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases to promote research examining the role that DEAD/H-box helicases have in immune homeostasis, activation, or function.
Within this NOSI’s scientific focus, projects of interest to NIAID include:
- Studying the role of DEAD/H-box helicases in immune system development, regulation, and function during homeostasis and in response to antigenic challenge (e.g., pathogens, vaccines, allergens, or autoantigens)
- Examining small molecule probes or agents targeting DEAD/H-box helicases to further define how these helicases modulate antimicrobial immunity, vaccine responsiveness, immune-mediated diseases, inflammation, immune system development, and tolerance
- Examining the role and underlying mechanism of DEAD/H-box helicases in hematopoietic stem cells’ self-renewal and differentiation, immune cell production, proliferation, composition, migration, and activation and function.
Closing date: This notice applies to standard due dates on or after October 5, 2021, and subsequent receipt dates through September 7, 2024
Funding Opportunity Announcement (FOA): PA-20-185 (R01), PA-20-195 (R21).
Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed), NIH
This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.
Closing date: October 1, 2021; June 15, 2022; June 15, 2023. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-HG-21-001
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed), NIH
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.
Closing date: Standard dates apply until May 08, 2023. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-20-131
2021 - 2022 Request for Proposals, Melanoma Research Alliance (MRA), US
The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.
The 2021 - 2022 award cycle, is anticipated to support at least $11.3 million in new funding. Proposals will be accepted for Team Science, Academic-Industry Partnership, Young Investigator, and Pilot Awards.
- October 6: Team Science Award Letters of Intent Due
- November 3: Young Investigator Award Eligibility Checklist Due to firstname.lastname@example.org.
- November 17: Young Investigator and Pilot Awards Full Proposals Due
- January 19: Team Science Award Full Proposals Due (from invited applicants)
Brian D Novis research grants, International Myeloma Foundation (IMF), US
The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. This year's awards will be $50,000 each for the junior grant and $80,000 for the senior grant.
Closing date: October 1, 2021.
This award aims to recognize the importance of good clinical research and to encourage young investigators in clinical studies. This award will consist of a commitment of $65,000 per year for two years, plus a $10,000 per year stipend to support education and research-related costs for a total of $150,000. Supplementation of the award with other grants is permissible, but to be eligible to apply for this award, the other grant source(s) cannot exceed $75,000 annually.
Closing date: October 1, 2021
Postdoc Fellowship for alternatives to animal research in human health and sex differences, American Fund for Alternatives to Animal Research (AFAAR), US
The American Fund for Alternatives to Animal Research (AFAAR) offer a $40,000, one-year postdoctoral fellowship grant (with possible renewal) to a woman interested in developing, validating, or using alternatives to animal methods in the investigation of human health or sex differences. Applicants must hold an interest in using or promoting non-animal alternatives in research.
Closing date: October 1, 2021
Neuroimaging and cerebrospinal fluid biomarker development programme, Alzheimer’s Drug Discovery Foundation, US
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
Specifically, this RFP focuses on:
- developing novel PET ligands for clinical trials
- supporting novel CSF biomarkers
- validating established MRI approaches in larger cohorts
Awards are typically worth up to USD 600,000 each for a period of one year, with potential for follow-on funding. Multi-year proposals may be considered.
Closing date: October 1, 2021 (LOI), December 3, 2021 (Full proposal).
Engagement award – capacity building, Patient-Centred Outcomes Research Institute (PCORI), US
The Engagement Awards program is now accepting Letters of Intent (LOIs) for the Engagement Award: Capacity Building funding opportunity. This opportunity aims to support projects that help communities increase their facility with and ability to participate across all phases of the PCOR/CER process. Applicants may propose projects for up to two years in duration and up to $250,000 in total costs. PCORI reminds prospective applicants that special areas of interest exist to encourage submissions on a topic, not to limit submissions to that topic only. PCORI welcomes Engagement Award: Capacity Building LOIs on all topics related to capacity building for patient-centered outcomes research/comparative clinical effectiveness research (PCOR/CER) that fall within the guidelines of the program.
Closing date: October 1, 2021 (LOI), January 10, 2022 (Full Proposal).